Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Almirall

This page shows the latest Almirall news and features for those working in and with pharma, biotech and healthcare.

Almirall eyes $62m takeover of multicytokine specialist Bioniz

Almirall eyes $62m takeover of multicytokine specialist Bioniz

Barcelona-based Almirall – which specialises in dermatology – says that the deal would expand its R&D pipeline with an additional three candidates on top of lead drug BNZ-1. ... Meanwhile, Almirall is in the launch phase for Ilumya/Ilumetri

Latest news

  • Amgen buys Danish partner Nuevolution for $167m Amgen buys Danish partner Nuevolution for $167m

    It will inherit established partnerships that Nuevolution also signed with the likes of Almirall, and Johnson &Johnson, according to the Danish firm’s website, and analysts at Edison said in March ... The Almirall partnership includes a RORγt

  • Big Pharma, Little Pharma Big Pharma, Little Pharma

    And that’s exactly what comes out of my research. The recent industry announcement that triggered this thought was from Almirall, the Spanish pharma company with fewer than 2, 000 employees

  • Almirall acquires Allergan’s dermatology portfolio for $650m Almirall acquires Allergan’s dermatology portfolio for $650m

    In a deal worth $650m, Spanish pharmaceutical company Almirall is set to buy Allergan’s US-based medical dermatology unit. ... If approved, Seysara could pull in predicted annual sales of $200m for Almirall.

  • Alnylam’s amyloidosis drug heads latest crop of CHMP approvals Alnylam’s amyloidosis drug heads latest crop of CHMP approvals

    There was also good news for Almirall, which got the nod for its delayed interleukin-23 inhibitor Ilumetri (tildrakizumab) as a treatment for moderate to severe plaque psoriasis, although it enters

  • Sun Pharma passes milestone with novel psoriasis drug approval Sun Pharma passes milestone with novel psoriasis drug approval

    Last November, Sun Pharma’s European licensee for tildrakizumab - Spain’s Almirall - said it expects the launch of the drug in the EU to be delayed by at least six months ... Almirall licensed European rights to the drug in July 2016 and filed for

More from news
Approximately 10 fully matching, plus 64 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2017 Deal Watch March 2017

    12. Symatese. Almirall. Development collaboration. Customised products in aesthetics. 8. AgaImmune.

  • Deal Watch December 2016 Deal Watch December 2016

    510. Nuevolution (Denmark). Almirall (Spain). Research collaboration. RORγt inhibitors for inflammatory skin diseases and psoriatic arthritis. ... $21m plus $80m equity. Biosimilars. Nuevolution. Almirall. $453m. $11.8m. Inhibitors to transcription

  • Deal Watch October 2016 Deal Watch October 2016

    $575m. $198m. 2.9. Respiratory 2014. Almirall. Products pipeline. $2, 100 milestones.

  • Deal Watch July 2016 Deal Watch July 2016

    Celyad. $311m. $12.5m. Almirall. Patagonia. $28m. $3.5m. Petra Pharma. Sprint BioScience. ... Almirall's initial expenditure has been a more modest $3.5m for this earlier stage product.

  • Stronger together Stronger together

    Also speaking at the eyeforpharma conference was Almirall's CEO Eduardo Sanchiz, who noted that, while patient-centricity is often talked about in the industry, “we have difficulties putting it in

More from intelligence
Approximately 2 fully matching, plus 10 partially matching documents found.

Latest appointments

  • New hires at Crescendo, Healx and Galecto New hires at Crescendo, Healx and Galecto

    Before that, he lead global R&D at Almirall, which involved 500 staff and the development and approval of several new drugs in a number of therapy areas.

  • Almirall appoints Peter Guenter as its CEO Almirall appoints Peter Guenter as its CEO

    Together with my team, I am convinced we will be able to fully unlock the value of Almirall.”. ... I am convinced he will bring what is needed to develop Almirall to the next level.”.

  • Ron Menezes joins Almirall’s Aqua Pharmaceuticals Ron Menezes joins Almirall’s Aqua Pharmaceuticals

    Pfizer. Eduardo Sanchiz, chief executive officer at Almirall, said: “We are very pleased to announce the appointment of Ron Menezes as the new president and GM of Aqua Pharmaceuticals. ... Sanchiz added: “Almirall continues to consider Aqua as a very

  • ThermiGen appoints Vladimir Paul-Blanc as president ThermiGen appoints Vladimir Paul-Blanc as president

    He will also serve as the Almirall-owned firm's general manager. Medical aesthetics technology firm ThermiGen has appointed Vladmir Paul-Blanc as its president and general manager. ... He said: “I couldn’t be more excitied to join Almirall and work

  • Caldan Therapeutics bolsters senior team Caldan Therapeutics bolsters senior team

    Most recently, Dr Connolly served as scientific leader with Almirall, based in Barcelona, Spain.

More from appointments
Approximately 5 fully matching, plus 5 partially matching documents found.

Latest from PMHub

  • EPG Health EPG Health

    Strategic planning - to ensure ongoing engagement and success. Alexion, Almirall, Alnylam, AstraZeneca, Bial, Biogen, Bluebird Bio, Boehringer Ingelheim, BMS, CSL Behring, Ferring, Four Health, GSK, HRA Pharma, Janssen, Leo Pharma, Lilly,

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Envision Pharma Group

We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....

Quick links